IL239211B - Anti-a–ntb antibodies and related compositions and methods - Google Patents

Anti-a–ntb antibodies and related compositions and methods

Info

Publication number
IL239211B
IL239211B IL239211A IL23921115A IL239211B IL 239211 B IL239211 B IL 239211B IL 239211 A IL239211 A IL 239211A IL 23921115 A IL23921115 A IL 23921115A IL 239211 B IL239211 B IL 239211B
Authority
IL
Israel
Prior art keywords
ntb
antibodies
methods
related compositions
compositions
Prior art date
Application number
IL239211A
Other languages
English (en)
Hebrew (he)
Other versions
IL239211A0 (en
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of IL239211A0 publication Critical patent/IL239211A0/en
Publication of IL239211B publication Critical patent/IL239211B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL239211A 2012-12-21 2015-06-04 Anti-a–ntb antibodies and related compositions and methods IL239211B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745239P 2012-12-21 2012-12-21
PCT/US2013/077264 WO2014100740A1 (en) 2012-12-21 2013-12-20 Anti-ntb-a antibodies and related compositions and methods

Publications (2)

Publication Number Publication Date
IL239211A0 IL239211A0 (en) 2015-07-30
IL239211B true IL239211B (en) 2020-08-31

Family

ID=50979291

Family Applications (2)

Application Number Title Priority Date Filing Date
IL239211A IL239211B (en) 2012-12-21 2015-06-04 Anti-a–ntb antibodies and related compositions and methods
IL271305A IL271305B (en) 2012-12-21 2019-12-10 Anti-ntb–a antibodies and related compositions and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL271305A IL271305B (en) 2012-12-21 2019-12-10 Anti-ntb–a antibodies and related compositions and methods

Country Status (10)

Country Link
US (4) US9708404B2 (show.php)
EP (1) EP2934585B1 (show.php)
JP (4) JP6449777B2 (show.php)
CN (2) CN105188749B (show.php)
AU (1) AU2013364043B2 (show.php)
CA (1) CA2893977C (show.php)
EA (1) EA031025B1 (show.php)
HK (1) HK1216850A1 (show.php)
IL (2) IL239211B (show.php)
WO (1) WO2014100740A1 (show.php)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101842114A (zh) * 2007-08-02 2010-09-22 阿雷斯托生物科学股份有限公司 治疗和诊断纤维化、肿瘤侵入、血管生成和转移的方法和组合物
WO2014100740A1 (en) 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
EP3191525B1 (en) * 2014-09-09 2019-08-28 Board of Regents, The University of Texas System Blocking monoclonal antibodies to agr2 and its receptor c4.4a
EP3110447B1 (en) * 2014-09-16 2020-04-29 Synermore Biologics Co., Ltd. Anti-egfr antibody and uses of same
SI3200822T1 (sl) * 2014-09-30 2021-10-29 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Vezavne molekule, posebno antiteles, vezanih na L1CAM (CD171)
EP3212668B1 (en) 2014-10-31 2020-10-14 AbbVie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
TWI721959B (zh) 2014-12-04 2021-03-21 美商健生生物科技公司 治療急性骨髓性白血病之抗ｃｄ３８抗體
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
BR112017027498A2 (pt) * 2015-06-30 2018-09-11 Seattle Genetics Inc anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença.
SMT202100192T1 (it) 2015-11-03 2021-05-07 Janssen Biotech Inc Formulazioni sottocutanee di anticorpi anti-cd38 e loro usi.
AU2018359527A1 (en) 2017-10-31 2020-05-07 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CN112041343B (zh) * 2018-02-13 2024-08-30 精密生物制品股份有限公司 用于靶向Treg细胞的方法和组合物
MX2021015501A (es) 2019-07-03 2022-04-20 Oxford Biotherapeutics Ltd Anticuerpos y metodos de uso.
WO2021066869A1 (en) * 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
US20230092356A1 (en) 2019-12-06 2023-03-23 Thoas Fioretos Novel agents and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5515508A (en) 1993-12-17 1996-05-07 Taligent, Inc. Client server system and method of operation including a dynamically configurable protocol stack
AU5752696A (en) 1995-05-18 1996-11-29 Regents Of The University Of Michigan, The Dna binding antibodies
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO2001053466A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Methods and materials relating to semaphorin-like polypeptides and polynucleotides
CA2398546A1 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to cd84-like polypeptides and polynucleotides
AU2001253362A1 (en) 2000-04-13 2001-10-30 Smith Kline Beecham Corporation Novel compounds
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6464770B1 (en) 2000-08-08 2002-10-15 Advanced Minerals Corporation Perlite products with controlled particle size distribution
AU2002216610A1 (en) 2000-09-01 2002-04-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7795412B2 (en) 2000-09-15 2010-09-14 Genentech, Inc. Nucleic acids encoding PRO6308 polypeptides and related vectors and host cells
EP1223218A1 (en) 2000-11-03 2002-07-17 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules and uses thereof
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
AU2002257088A1 (en) 2001-03-12 2002-09-24 Incyte Genomics, Inc. Immunoglobulin superfamily proteins
US7138243B2 (en) 2001-07-19 2006-11-21 Innate Pharma, S.A. NTB-A, a surface molecule involved in natural killer cells activity
MXPA04001986A (es) 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
EP1483407A4 (en) 2002-02-14 2006-11-15 Nuvelo Inc THERAPY AND DIAGNOSTIC PROCEDURES
EP1572130A4 (en) 2002-07-08 2008-07-02 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNEAL DISEASES
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
CA2500521A1 (en) 2002-10-02 2004-09-23 Nuvelo, Inc. Novel nucleic acids and polypeptides
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ZA200603619B (en) 2003-11-06 2008-10-29 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US20080299042A1 (en) 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
US7807165B2 (en) 2004-07-30 2010-10-05 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
AU2006269422B2 (en) 2005-07-07 2012-12-06 Seagen Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
EP1940470B1 (en) * 2005-09-26 2013-04-17 Medarex, Inc. Antibody-drug conjugates and their use
US7847067B2 (en) * 2006-08-28 2010-12-07 ARCA Biopharma Antibodies to NTB-A
EP2206590A4 (en) * 2007-10-03 2014-02-12 Boada Germans Sa HAND CUTTING TOOL FOR CERAMIC
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
AU2008311815B2 (en) 2007-10-19 2014-02-06 Seagen Inc. CD19 binding agents and uses thereof
NZ591153A (en) 2008-08-29 2012-12-21 Symphogen As Anti-cd5 antibodies
WO2010032698A1 (ja) * 2008-09-16 2010-03-25 三井化学株式会社 植物由来原料から乳酸を生産する方法及び乳酸生産細菌
US20120128689A1 (en) 2009-04-01 2012-05-24 Glaxo Group Limited Anti-il-23 immunoglobulins
MX2011013781A (es) 2009-06-17 2012-05-29 Abbott Biotherapeutics Corp Anticuerpos anti-vegf y sus usos.
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US8303093B2 (en) * 2009-12-15 2012-11-06 Xerox Corporation Print head having a polymer layer to facilitate assembly of the print head
CN102939299B (zh) 2010-01-18 2016-04-20 诺沃—诺迪斯克保健股份有限公司 凝血因子的纯化
UA108227C2 (xx) * 2010-03-03 2015-04-10 Антигензв'язуючий білок
US8986697B2 (en) 2010-04-15 2015-03-24 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease
US9243057B2 (en) * 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
KR101398363B1 (ko) * 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
TWI664191B (zh) 2010-11-22 2019-07-01 天賜製藥公司 Ｎｋ細胞調節治療及治療血液惡性疾病之方法
JP6261499B2 (ja) 2011-07-11 2018-01-17 グレンマーク ファーマシューティカルズ， エセ．アー． Ｏｘ４０と結合する抗体およびその使用
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2014100740A1 (en) * 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
ES2612918T3 (es) * 2013-07-10 2017-05-19 Miltenyi Biotec Gmbh Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles
BR112017027498A2 (pt) * 2015-06-30 2018-09-11 Seattle Genetics Inc anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença.

Also Published As

Publication number Publication date
US20150376276A1 (en) 2015-12-31
US9708404B2 (en) 2017-07-18
CN107880126B (zh) 2021-03-30
IL271305B (en) 2021-01-31
EA031025B1 (ru) 2018-11-30
JP2016503067A (ja) 2016-02-01
CA2893977C (en) 2024-02-13
EP2934585B1 (en) 2018-06-13
JP6817674B2 (ja) 2021-01-20
CN105188749B (zh) 2017-12-19
US20170320944A1 (en) 2017-11-09
JP2022066565A (ja) 2022-04-28
IL239211A0 (en) 2015-07-30
JP2020055870A (ja) 2020-04-09
JP6449777B2 (ja) 2019-01-09
US20230105802A1 (en) 2023-04-06
HK1216850A1 (zh) 2016-12-09
EA201591191A1 (ru) 2015-11-30
US20190375841A1 (en) 2019-12-12
CN107880126A (zh) 2018-04-06
AU2013364043B2 (en) 2018-01-04
WO2014100740A1 (en) 2014-06-26
EP2934585A1 (en) 2015-10-28
JP2019014752A (ja) 2019-01-31
IL271305A (en) 2020-01-30
EP2934585A4 (en) 2016-07-13
CA2893977A1 (en) 2014-06-26
US10435468B2 (en) 2019-10-08
AU2013364043A1 (en) 2015-06-18
CN105188749A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
IL271305B (en) Anti-ntb–a antibodies and related compositions and methods
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
IL266893B (en) Meditops and Meditop binding antibodies and their use
IL259436A (en) Antibodies against 3angptl and their uses
ZA201502880B (en) Compositions and methods for immunotherapy
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
IL232399A0 (en) Anti-2fgfr antibodies and their use
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
IL254416B (en) Anti-asic1 antibodies and their uses
ZA201405554B (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
IL234695B (en) Antigen compositions and methods
GB201315350D0 (en) Methods and compositions
GB201315347D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
GB201208372D0 (en) Antibodies and uses thereof
GB201116340D0 (en) Compositions and methods
GB201209584D0 (en) Modified antibodies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed